Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regenerative Medical Technology (RMTG) FCF Margin (2018 - 2025)

Historic FCF Margin for Regenerative Medical Technology (RMTG) over the last 8 years, with Q3 2025 value amounting to 36.3%.

  • Regenerative Medical Technology's FCF Margin fell 585400.0% to 36.3% in Q3 2025 from the same period last year, while for Sep 2025 it was 12.7%, marking a year-over-year decrease of 124700.0%. This contributed to the annual value of 15.47% for FY2024, which is 488600.0% up from last year.
  • Per Regenerative Medical Technology's latest filing, its FCF Margin stood at 36.3% for Q3 2025, which was down 585400.0% from 60.81% recorded in Q2 2025.
  • In the past 5 years, Regenerative Medical Technology's FCF Margin registered a high of 22.24% during Q3 2024, and its lowest value of 3485.48% during Q1 2021.
  • Moreover, its 5-year median value for FCF Margin was 41.67% (2022), whereas its average is 592.5%.
  • Its FCF Margin has fluctuated over the past 5 years, first tumbled by -32119900bps in 2021, then soared by 34299600bps in 2022.
  • Over the past 5 years, Regenerative Medical Technology's FCF Margin (Quarter) stood at 3463.06% in 2021, then surged by 99bps to 33.1% in 2022, then plummeted by -54bps to 50.91% in 2023, then soared by 143bps to 21.8% in 2024, then tumbled by -267bps to 36.3% in 2025.
  • Its FCF Margin stands at 36.3% for Q3 2025, versus 60.81% for Q2 2025 and 4.19% for Q1 2025.